2020 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

Emmanuel J. Favaloro

doi:10.1055/s-0040-1712971

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2020; 46(04): 383-392
DOI: 10.1055/s-0040-1712971

Editorial

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

2020 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

Emmanuel J. Favaloro

¹Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, Australia

› Author Affiliations

Abstract

Full Text

References

References
1 Lippi G, Favaloro EJ, Sanchis-Gomar F. Sudden cardiac and noncardiac death in sports: epidemiology, causes, pathogenesis, and prevention. Semin Thromb Hemost 2018; 44 (08) 780-786
2 Schreiber K, Breen K, Cohen H. , et al. HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost 2017; 43 (06) 562-571
3 Harenberg J, Schreiner R, Hetjens S, Weiss C. Detecting anti-IIa and anti-Xa direct oral anticoagulant (DOAC) agents in urine using a DOAC dipstick. Semin Thromb Hemost 2019; 45 (03) 275-284
4 Gosselin RC, Adcock D, Dorgalaleh A. , et al. International council for standardization in haematology recommendations for hemostasis critical values, tests, and reporting. Semin Thromb Hemost 2020; 46 (04) 398-409
5 Harenberg J. Development of new anticoagulants: present and future. Semin Thromb Hemost 2008; 34 (08) 779-793
6 Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation. Semin Thromb Hemost 2018; 44 (01) 20-29
7 Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009; 35 (02) 189-203
8 Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012; 38 (08) 865-883
9 Lippi G, Danese E, Favaloro EJ. Harms and benefits of using aspirin for primary prevention of cardiovascular disease: a narrative overview. Semin Thromb Hemost 2019; 45 (02) 157-163
10 Gosselin RC, Marlar RA. Preanalytical variables in coagulation testing: setting the stage for accurate results. Semin Thromb Hemost 2019; 45 (05) 433-448
11 Mannucci PM, Mancuso ME, Santagostino E, Franchini M. Innovative pharmacological therapies for the hemophilias not based on deficient factor replacement. Semin Thromb Hemost 2016; 42 (05) 526-532
12 Elewa H, Ahmed D, Barnes GD. Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting: searching for the best combination. Semin Thromb Hemost 2016; 42 (06) 662-670
13 Bunimov N, Fuller N, Hayward CP. Genetic loci associated with platelet traits and platelet disorders. Semin Thromb Hemost 2013; 39 (03) 291-305
14 Lippi G, Salvagno GL, Gelati M, Poli G, Giavarina D, Favaloro EJ. Analytical assessment of the New Roche Cobas t 711 fully automated coagulation analyzer. Semin Thromb Hemost 2019; 45 (03) 308-314
15 Schulman S. Update on the treatment of venous thromboembolism. Semin Thromb Hemost 2016; 42 (08) 891-898
16 Raskob GE, Angchaisuksiri P, Blanco AN. , et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Semin Thromb Hemost 2014; 40 (07) 724-735
17 Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost 2014; 40 (03) 277-283
18 Batorova A, Jankovicova D, Morongova A. , et al. Inhibitors in severe hemophilia a: 25-year experience in Slovakia. Semin Thromb Hemost 2016; 42 (05) 550-562
19 Favaloro EJ, Pasalic L, Curnow J. Type 2M and type 2A von Willebrand disease: similar but different. Semin Thromb Hemost 2016; 42 (05) 483-497
20 Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34 (08) 709-733
21 Tersteeg C, Fijnheer R, Pasterkamp G. , et al. Keeping von Willebrand Factor under control: alternatives for ADAMTS13. Semin Thromb Hemost 2016; 42 (01) 9-17
22 Harenberg J, Du S, Krämer S, Weiss C, Krämer R, Wehling M. Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants. Semin Thromb Hemost 2015; 41 (02) 228-236
23 van der Vorm LN, Huskens D, Kicken CH. , et al. Effects of repeated bouts of exercise on the hemostatic system. Semin Thromb Hemost 2018; 44 (08) 710-722
24 Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. Semin Thromb Hemost 2008; 34 (08) 772-778
25 Zolfaghari S, Harenberg J, Froelich L, Wehling M, Weiss C. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy. Semin Thromb Hemost 2014; 40 (01) 121-128
26 Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies. Semin Thromb Hemost 2019; 45 (07) 661-673
27 Russo V, Attena E, Mazzone C. , et al. Nonvitamin K antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves/prior surgical valve repair: a multicenter clinical practice experience. Semin Thromb Hemost 2018; 44 (04) 364-369
28 Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30 (05) 579-589
29 Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997; 23 (04) 349-356
30 Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. Semin Thromb Hemost 2003; 29 (05) 435-450
31 Bolliger D, Tanaka KA. Point-of-care coagulation testing in cardiac surgery. Semin Thromb Hemost 2017; 43 (04) 386-396
32 Reynen E, James P. Von Willebrand disease and pregnancy: a review of evidence and expert opinion. Semin Thromb Hemost 2016; 42 (07) 717-723
33 Franchini M, Mannucci PM. The history of hemophilia. Semin Thromb Hemost 2014; 40 (05) 571-576
34 Bikdeli B, Abou Ziki MD, Lip GYH. Pulmonary embolism and atrial fibrillation: two sides of the same coin? A systematic review. Semin Thromb Hemost 2017; 43 (08) 849-863
35 Marlar RA, Clement B, Gausman J. Activated partial thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations. Semin Thromb Hemost 2017; 43 (03) 253-260
36 Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost 2019; 45 (01) 86-93
37 McEwen BJ. The influence of herbal medicine on platelet function and coagulation: a narrative review. Semin Thromb Hemost 2015; 41 (03) 300-314
38 Maclachlan KH, Stevens HP, Tran HA, Chunilal SD. Weight-based enoxaparin for venous thromboembolism in obesity gives similar anti-Xa levels to patients <100 kg, with no increase in major bleeding. Semin Thromb Hemost 2019; 45 (01) 94-99
39 Cohen H, Efthymiou M, Gates C, Isenberg D. Direct oral anticoagulants for thromboprophylaxis in patients with antiphospholipid syndrome. Semin Thromb Hemost 2018; 44 (05) 427-438
40 Van Cott EM, Roberts AJ, Dager WE. Laboratory monitoring of parenteral direct thrombin inhibitors. Semin Thromb Hemost 2017; 43 (03) 270-276
41 Radulescu VC. Anticoagulation therapy in children. Semin Thromb Hemost 2017; 43 (08) 877-885
42 Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost 2006; 32 (Suppl. 01) 3-15
43 Arachchillage DRJ, Makris M. Inherited thrombophilia and pregnancy complications: should we test?. Semin Thromb Hemost 2019; 45 (01) 50-60
44 Kershaw G, Orellana D. Mixing tests: diagnostic aides in the investigation of prolonged prothrombin times and activated partial thromboplastin times. Semin Thromb Hemost 2013; 39 (03) 283-290
45 Lippi G, Plebani M, Favaloro EJ. Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. Semin Thromb Hemost 2013; 39 (03) 258-266
46 Molhoek JE, de Groot PG, Urbanus RT. The lupus anticoagulant paradox. Semin Thromb Hemost 2018; 44 (05) 445-452
47 Marlar RA, Gausman JN, Engel JW. Validation of hemostasis and coagulation assays: recommendations and guidelines. Semin Thromb Hemost 2014; 40 (02) 186-194
48 Favaloro EJ, Kershaw G, Mohammed S, Lippi G. How to optimize activated partial thromboplastin time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors. Semin Thromb Hemost 2019; 45 (01) 22-35
49 Anker-Møller T, Troldborg A, Sunde N, Hvas AM. Evidence for the use of tranexamic acid in subarachnoid and subdural hemorrhage: a systematic review. Semin Thromb Hemost 2017; 43 (07) 750-758
50 Lippi G, Franchini M, Favaloro EJ. Diagnostics of inherited bleeding disorders of secondary hemostasis: an easy guide for routine clinical laboratories. Semin Thromb Hemost 2016; 42 (05) 471-477
51 Favaloro EJ, Lippi G. Editorial compilation VI. Semin Thromb Hemost 2019; 45 (01) 5-9
52 Schulman S. Recent advances in thrombosis and hemostasis-part IV. Semin Thromb Hemost 2019; 45 (02) 130-131
53 Kwaan HC, Teruya J. Perturbation of hemostatic function by nonbiologic surfaces. Semin Thromb Hemost 2018; 44 (01) 5-6
54 Adcock DM, Gosselin RC. Laboratory assessment of hemostatic and anticoagulant therapy. Semin Thromb Hemost 2017; 43 (03) 242-244
55 Schulman S, Islam MS. Recent advances in thrombosis and hemostasis-part II. Semin Thromb Hemost 2017; 43 (08) 809-810
56 Lisman T, de Moerloose P. The role of fibrinogen and factor XIII in hemostasis, and the identification and treatment of associated disorders. Semin Thromb Hemost 2016; 42 (04) 331-332
57 Othman M, McLintock C, Kadir R. Thrombosis and hemostasis related issues in women and pregnancy. Semin Thromb Hemost 2016; 42 (07) 693-695
58 Favaloro EJA. 2018 update on the editorial and publication policy of seminars in thrombosis and hemostasis. Semin Thromb Hemost 2018; 44 (04) 307-311
59 International Council for Standardization in Haematology (ICSH) website. Available at: https://icsh.org/ . Accessed January 26, 2020